Current status of human papillomavirus vaccination implementation in central and eastern Europe.
暂无分享,去创建一个
M. Poljak | K. Seme | Ermina Iljazović | Z. Molnár | V. Kesic | D. Laušević | J. Částková | B. Kaić | V. Učakar | M. Spaczyński | G. Dimitrov | P. J. Maver | H. Hudecová | Tina Korać | J. Perevoščikovs | Irina Filippova | N. Kuprevičienė | A. Canton | Venera Stefanova | E. Iljazović
[1] M. Poljak,et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. , 2013, Vaccine.
[2] H. Cubie,et al. Human papillomavirus vaccine introduction--the first five years. , 2012, Vaccine.
[3] Z. Kaló,et al. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary , 2012, BMC Public Health.
[4] P. Lopalco,et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[5] A. Mrhar,et al. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. , 2010, European journal of public health.
[6] E. Dasbach,et al. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary , 2010, Journal of medical economics.
[7] B Romanowski,et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.
[8] V. Usonis,et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines , 2009, European Journal of Pediatrics.
[9] E. Dasbach,et al. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. , 2008, Asian Pacific journal of cancer prevention : APJCP.
[10] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[11] F. X. Bosch,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .
[12] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[13] G. Sanders,et al. Evaluating Human Papillomavirus Vaccination Programs , 2004, Emerging infectious diseases.
[14] Human papillomavirus and cervical cancer. Summary report. , 1989, IARC scientific publications.